Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. AMZN
10. META

Go back to Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

Enanta Pharma (ENTA) Misses Q4 EPS by 9c, Revenues Miss

November 21, 2019 4:01 PM EST

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $0.44, $0.09 worse than the analyst estimate of $0.53. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.94 million.

Initiation of RSVP, a Phase 2b study of EDP-938 in adult outpatients with RSVEDP-297 selected as follow-on FXR agonist with differentiated preclinical profileRoyalty revenue for the quarter was $51.3 millionCash and marketable securities totaled approximately $400 million at September 30, 2019

During 2019, we successfully... More